Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Eye

Volumn 23, Issue 11, 2009, Pages 2042-2045

  Wu, P C ^a   Chen, Y J ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Avastin; Bevacizumab; Choroidal neovascularization; Intravitreal injection; Myopia

Indexed keywords

BEVACIZUMAB;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL EXAMINATION; DRUG EFFICACY; DRUG SAFETY; EYE; EYE FUNDUS; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; INJECTION; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; PHOTOGRAPHY; RETINA; SUBRETINAL NEOVASCULARIZATION; THICKNESS; VISION; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHOROIDAL NEOVASCULARIZATION; FEMALE; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 70349131895     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.404     Document Type: Article

References (11)

1. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103(8): 1241-1244.
2. Tabandeh H, Flynn Jr HW, Scott IU, Lewis ML, Rosenfeld PJ, Rodriguez F et al. Visual acuity outcomes of patients 50 years of age and older with high myopia and untreated choroidal neovascularization. Ophthalmology 1999; 106(11): 2063-2067.
3. Yoshida T, Ohno-Matsui K, Ohtake Y, Takashima T, Futagami S, Baba T et al. Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups. Ophthalmology 2002; 109(4): 712-719.
4. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trialFVIP report no. 3. Ophthalmology 2003; 110(4): 667-673.
5. Wu P, Chen Y, Chen C, Chen YH, Kao ML, Shin SJ et al. Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: 1 and 2 year follow-up. Clin Exp Ophthalmol 2008; 36(5): 443-448.
6. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: Six-month results of a prospective pilot study. Ophthalmology 2007; 114(12): 2190-2196.
7. Hernandez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, Fromow-Guerra J, Amaya-Espinosa A, Sol?́s-Vivanco A et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007; 27(6): 707-712.
8. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147(1): 84-93.
9. Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results. Am J Ophthalmol 2009; 147(1): 94-100.
10. Costa RA, Jorge R, Calucci D, Cardillo JA, Melo Jr LA, Scott IU. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006; 47(10): 4569-4578.
11. Yoganathan P, Fastenberg DM, Ferrone PJ. Intravitreal Bevacizumab 2.5 versus 1.25mg in Exudative Age-Related Macular Degeneration: Safety and Efficacy. Program and Abstracts of the Association for Research in Vision and Ophthalmology. Fort Lauderdale: Florida, 2007 (Abstract 166).